Revelation Biosciences (REVB) Short-term Investments (2020 - 2021)
Revelation Biosciences (REVB) posted quarterly Short-term Investments of $19749.0 for Q3 2021, down 93.45% quarter-over-quarter from $301716.0 in Q2 2021.
Revelation Biosciences (REVB) Short-term Investments (2020 - 2021) Analysis & Trends
Revelation Biosciences (REVB) has reported Short-term Investments for 2 consecutive years, with $19749.0 the latest figure, recorded in Q3 2021.
- In Q3 2021, Short-term Investments changed N/A year-over-year to $19749.0; the TTM figure through Sep 2021 stood at $19749.0 (changed N/A YoY), while the FY2020 annual figure was $525287.0, changed N/A from the prior year.
- Short-term Investments retreated to $19749.0 in Q3 2021 per REVB's latest filing, from $301716.0 in the prior quarter.
- Across five years, Short-term Investments topped out at $525287.0 in Q4 2020 and bottomed at $19749.0 in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Revelation Biosciences | 4.17 Mn | -7.33 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 19,749.00 |
| Jun 30, 2021 | 301,716.00 |
| Mar 31, 2021 | 390,649.00 |
| Dec 31, 2020 | 525,287.00 |